Howard Hughes Holdings (NYSE:HHH) Stock, Quote.Headers.trade-ideas

Howard Hughes Holdings

Howard Hughes

Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments, and Seaport.

bill ackman ai3

Long Ideas

Specialty ETFs

Hedge Funds

Trading Ideas

ETFs

GOOG

GOOGL

Bill Ackman could be pivoting from a closed-end fund IPO to potentially launching a Pershing Square ETF, aiming for increased accessibility, liquidity, and cost efficiency for investors.

Bill Ackman Weighs Pivot To ETF After Abandoning Closed-End Fund IPO: Report

Homeowner and Reverse Mortgage Scams

Equities

Macro Economic Events

Mid Cap

REIT

Sector ETFs

Bonds

Small Cap

Treasuries

Econ #s

Economics

Markets

Real Estate

CHCT

OPEN

PKST

iShares FTSE NAREIT Residential PLUS Capped Index Fund

Bond yields drop on expectations of Fed rate cut, leading to lowest mortgage rates in over a year and surge in mortgage applications for both new and refinancing loans.

Mortgage Rates Fall To 15-Month Lows, Boost Homebuyer Demand As Federal Reserve Hints At Rate Cuts

Bill Ackman

News

PSHZF

All of Pershing Square&#39;s holdings except real-estate development and management company Howard Hughes saw book profits in the first quarter.

Bill Ackman&#39;s Pershing Square Q1 Shake-Up: Home Retailer Dumped, Hot Restaurant Stake Trimmed And A &#39;Magnificent 7&#39; Holding Juggled

Howard Hughes Holdings Inc

37 Capital Inc

HC Wainwright &amp; Co. analyst Robert Burns reiterates BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and maintains $113 price target.

Price Target

Reiteration

Analyst Ratings

BNTX

HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target

Morgan Stanley analyst Robert Kad downgrades EnLink Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENLC#NYSE">ENLC</a>) from Overweight to Equal-Weight and maintains the price target from $16 to $16.

Downgrades

ENLC

Morgan Stanley Downgrades EnLink Midstream to Equal-Weight, Maintains Price Target to $16

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) with a Buy and maintains $12 price target.

IOBT

HC Wainwright & Co. Reiterates Buy on IO Biotech, Maintains $12 Price Target

Morgan Stanley analyst Devin McDermott upgrades Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) from Underweight to Equal-Weight and maintains the price target from $24 to $24.

Upgrades

Morgan Stanley Upgrades Kinder Morgan to Equal-Weight, Maintains Price Target to $24

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

Morgan Stanley analyst Robert Kad upgrades ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) from Equal-Weight to Overweight and raises the price target from $103 to $111.

Morgan Stanley Upgrades ONEOK to Overweight, Raises Price Target to $111

Earnings

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SunCar Technology Reported 27% Revenue Growth To $203.1M In First Half of 2024, EPS Loss Of $(0.67)

This multi-year agreement extends the longstanding relationship between the two companies, encompassing Adeia&#39;s expansive media IP portfolio.
The renewed agreement covers a wide range of technologies within Adeia&#39;s media IP portfolio, including innovations in digital video, content discovery, and smart home technologies.&nbsp;

ADEA

Adeia Reports Renewal Of Its Intellectual Property License Agreement With LG Electronics

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) with a Outperform and lowers the price target from $50 to $44.

ALLY

Keefe, Bruyette & Woods Maintains Outperform on Ally Financial, Lowers Price Target to $44

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) with a Buy and maintains $22 price target.

ACRV

HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $22 Price Target

Shares of Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) moved sharply lower <a href="https://www.benzinga.com/premarket">in premarket trading</a> on Monday, with a slew of factors weighing down on them.
Preorders for Apple&#8217;s latest iPhone iterations began last Friday and an early tally by some analysts does not paint a positive picture. TFI Securities analyst Ming-Chi Kuo said in a social media post late Sunday that<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40872864/apple-staring-at-lower-than-expected-demand-for-iphone-16-pro-and-pro-max-in-the-fi"> iPhone 16 preorders were 37 million units, down 12.7% from the iPhone 15 first-week preorders. </a>The year-over-year drop is due to lower-than-expected demand for the iPhone 16 Pro series. The analyst based his data on the latest supply chain survey and pre-order results from Apple's official websites.
See Also: <a href="https://www.benzinga.com/money/best-tech-stocks">Best Tech Stocks Right Now</a>
Kuo noted that the soft Max series demand is due to the fact that Apple Intelligence, the major selling point, is not available at launch. He also pointed to intense competition in China, especially from Huawei and other home-grown rivals. 
Also, data from China, Apple&#8217;s key market, on Saturday showed the economy is still struggling with softness, and this along with competition could pressure the company&#8217;s sales in the region.
Some of the weakness may have to do with the across-the-sector negativity, with investors fearing that a Federal Reserve rate cut could stall the tech rally as they shift their investment dollars into underperforming, small-cap stocks.
In premarket trading, Apple lost its flavor and fell 1.93% to $218.20, according to<a href="https://benzinga.grsm.io/register174"> Benzinga Pro data.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40869770/no-razzle-dazzle-with-latest-iphone-but-apple-wowed-with-these-2-glowtime-announcements-says-gur">No &#8216;Razzle-Dazzle&#8217; With Latest iPhone, But Apple Wowed With These 2 &#8216;Glowtime&#8217; Announcements, Says Gurman</a></li>
</ul>
Image via Shutterstock

Movers

Tech

AAPL

Apple Shares Slide In Monday Premarket: What's Souring Sentiment?

<ul>
<li>Docetaxel remains the standard of care for patients with 2L/3L NSCLC without targetable alterations despite severe neutropenia (&gt;40%) that greatly impair patients' quality of life.&nbsp;</li>
<li>Six recent phase 3 studies in patients with EGFR wild-type NSCLC who were previously treated with immune checkpoint inhibitors failed to show overall survival (OS) benefit compared with docetaxel (SAPPHIRE, LEAP-008, CONTACT01, EVOKE-01, CARMEN-LC03, and CANOPY-2). Two phase 3 studies (LUNAR and TROPION-Lung01) showed positive but mixed outcomes compared with docetaxel.</li>
</ul>

Biotech

Health Care

General

BYSI

Beyondspring Presented Final Data On Dublin-3 Study (2L/3L EGFR wild-type NSCLC) Focusing On Safety Outcomes At European Society For Medical Oncology

Selection of the development candidate triggered a&nbsp;$3 million&nbsp;milestone payment to Voyager, which the Company expects to receive in the&nbsp;fourth quarter&nbsp;of 2024.
Voyager is eligible to receive additional future development and commercialization milestone payments based on the further advancement of this program.
Under the terms of the 2023 collaboration agreement, for each of the three undisclosed programs, Voyager is eligible to receive up to&nbsp;$175 million&nbsp;in potential development milestone payments plus substantial potential commercial milestone payments, as well as tiered high single-digit to mid-teens royalties on U.S. net sales and mid-single-digit to low double-digit royalties on ex-U.S. net sales. Neurocrine Biosciences will fund the development of each program.

VYGR

Voyager Says Joint Steering Committee With Collaborator Neurocrine Selected A Development Candidate In Gene Therapy Program; Selection Of Candidate Triggered $3M Milestone Payment

Deutsche Bank analyst Chris Woronka maintains Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) with a Hold and lowers the price target from $218 to $194.

Deutsche Bank Maintains Hold on Vail Resorts, Lowers Price Target to $194

HC Wainwright &amp; Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Buy and raises the price target from $18 to $19.

RLAY

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $19

Former White House Communications Director Anthony Scaramucci predicts more GOP officials breaking away from former President Donald Trump, with a prediction market showing Senator Mitt Romney (R-Utah) may <a href="https://www.benzinga.com/general/entertainment/24/09/40824581/taylor-swifts-endorsement-of-kamala-harris-drives-over-330k-visitors-to-vote-gov">endorse Vice President Kamala Harris</a>.
What Happened: The <a href="https://polymarket.com/event/will-mitt-romney-endorse-kamala?tid=1726475837488">market</a> shows a 42% chance as of Sep. 16., indicating that speculators ascribe a fair chance to a potential Romney endorsement.
This comes as political tensions within the GOP continue to escalate, with more figures distancing themselves from 
Scaramucci <a href="https://x.com/Scaramucci/status/1835360231272124549">stated</a> on X, "More GOP elected officials will start to denounce Trump. Bookmark this." The remark comes amid growing speculation that prominent Republicans may break with Trump, especially in light of Romney&#8217;s repeated public criticisms of the former president.
Romney has a history of lambasting Trump, having referred to him as a &#8220;failure of character&#8221; <a href="https://www.benzinga.com/news/23/10/35366702/mitt-romney-blasts-donald-trump-represents-a-failure-of-character">in a recent interview</a>.
The Utah Senator&#8217;s sentiments reflect his estrangement from the modern Republican Party, which he no longer feels aligns with the values of past GOP leaders like Ronald Reagan and George H.W. Bush. 
Romney ruled out a 2024 presidential bid, humorously stating, "Perhaps if Godzilla comes in and removes all the other candidates…no, I'm not running for president."
Given Romney&#8217;s estrangement from Trump and the Republican Party's current direction, it isn't entirely out of the question, according to market speculation.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read:<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40860002/heres-how-much-donald-trumps-crypto-portfolio-is-down-from-the-top-spoiler-its-millions-an"> Here&#8217;s How Much Donald Trump&#8217;s Crypto Portfolio Is Down From The Top (Spoiler: It&#8217;s Millions And Millions Of Dollars)</a>
Why it matters: The potential for high-profile Republican endorsements of Democratic candidates could significantly impact the 2024 election landscape.
Interestingly, recent polls show Vice President Harris gaining traction on economic issues, particularly among small business owners. 
A USA Polling survey <a href="https://x.com/USA_Polling/status/1835516983309210035">indicates</a> that 49% of small business owners approve of Harris&#8217;s handling of the economy, with a significant number believing she understands the challenges facing small businesses.
This unexpected economic competence could make Harris an attractive option for moderate Republicans disillusioned with their party&#8217;s current direction. 
What&#8217;s Next: This growing division within the GOP, exemplified by figures like Mitt Romney, will likely be a key topic at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets </a>event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40859716/tether-hires-paypal-veteran-jesse-spiro-as-regulatory-scrutiny-continues">Tether Hires PayPal Veteran Jesse Spiro As Regulatory Scrutiny Continues</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Anthony Scaramucci: 'More GOP Officials Will Start To Denounce Trump' — Senator Mitt Romney May Be One Of Them, Polymarket Traders Think

TECH

ScaleReady And Bio-Techne Launched The G-Rex Optimized ProPak GMP Cytokines, Ideally Tailored To High-Efficiency Closed System Cell And Gene-modified Cell Therapy Manufacturing

CGEM

Cullinan Therapeutics Has Submitted An Investigational New Drug Application To FDA To Evaluate Its CD19xCD3 Bispecific T Cell Engager, CLN-978, For Systemic Lupus Erythematosus

TNXP

Tonix Pharmaceuticals Says World Health Organization's Preferred Target Product Profile, Aligns With The Characteristics Of TNX-801 (Horsepox, Live Virus) Vaccine, Which Is Being Developed For Preventing Mpox

CANF

Israeli Ministry Of Health Approves Can-Fite Biopharma's Phase 2A Clinical Trial With Orally-administered Namodenoson In The Treatment Of Pancreatic Carcinoma, Study Will Aim To Establish Safety And Clinical Efficacy

Eyes On The FOMC, Tech Heavyweight Reports, And OPEC+ Meeting

Howard Hughes Holdings: Not My Favorite From This Superinvestor

Howard Hughes gains as Pershing Square considers go private deal

Howard Hughes gains as Pershing Square considers go-private deal

Howard Hughes board forms special committee on potential take-private offer

An update from Howard Hughes Holdings (HHH) is now available. The provided information is intended for informational purposes only and will not be ...

Howard Hughes Holdings Issues Regulation FD Disclosure Notice

Warner Bros. eyes spending $8.5B on Las Vegas film studio if tax credit bill passes

Pershing Square Holdings H1 2024 Letter To Shareholders

Howard Hughes: A Pure-Play MPC  With Decades-Long Growth Runway

Tracking Bill Ackman's Pershing Square 13F Portfolio - Q2 2024 Update

ANRO

BAMGF

BAMKF

BKAMF

BKFAF

BKFDF

BKFOF

BKFPF

BRCFF

BROXF

BRPSF

BXDIF

CIFR

FMCC

FMCCG

FMCCH

FMCCI

FMCCJ

FMCCK

FMCCL

FMCCM

FMCCN

FMCCO

FMCCP

FMCCS

FMCCT

FMCKI

FMCKJ

FMCKK

FMCKL

FMCKM

FMCKN

FMCKO

FMCKP

FNMA

FNMAG

FNMAH

FNMAI

FNMAJ

FNMAK

FNMAL

FNMAM

FNMAN

FNMAO

FNMAP

FNMAS

FNMAT

FNMFM

FNMFN

FNMFO

FREGP

FREJN

FREJO

FREJP

SBUX

SONY

SOUN

SPOT

UMGNF

UNVGY

Dividends

Press Releases

Howard Hughes Holdings Inc. Board of Directors Approves Separation of Seaport Entertainment Group Inc.

Howard Hughes Holdings Inc. Announces Change to Seaport Entertainment Group Inc.'s Post-spinoff Stock Exchange

Howard Hughes Holdings Inc. Reports Second Quarter 2024 Results

Howard Hughes Holdings Announces Completion of Spinoff of Seaport Entertainment Group

Seaport Entertainment Group Completes Separation From Howard Hughes Holdings

RCLCO Mid-Year Report Ranks Summerlin® and Bridgeland® Among Nation's Top-Selling Master Planned Communities

Howard Hughes Holdings Forms Special Committee to Evaluate Potential Take-Private

Howard Hughes Holdings Inc. Appoints Charley Freericks as President of Phoenix Region

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Howard Hughes Holdings Inc. (HHH) and Encourages Long-Term Investors to Contact the Firm

Summerlin® Becomes Nevada's First Master Planned Community to Achieve LEED Precertification from U.S. Green Building Council

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Howard Hughes Holdings

Howard Hughes Holdings (HHH) Forecast

Howard Hughes Holdings (NYSE:HHH) Stock, Quote.Headers.trade-ideas